Top Markets
Coin of the day
Sesen Bio, Inc. Sesen Bio, Inc.

Sesen Bio, Inc.

SESN
Hisse Senetlerindeki Sıralama #34230
Sesen Bio, Inc. is a clinical-stage biotechnology firm deeply involved in the... Sesen Bio, Inc. is a clinical-stage biotechnology firm deeply involved in the creation, advancement, and eventual market launch of targeted fusion protein therapeutics (TFPTs). Their primary aim is to combat various forms of cancer. Their flagship experimental drug, Vicineum, is a locally administered targeted fusion protein currently undergoing Phase III clinical trials. It targets several conditions, including non-muscle invasive bladder cancer that has not responded to bacillus Calmette-Guérin (BCG) treatment, non-muscle invasive carcinoma in situ of the bladder in patients who previously received BCG, and squamous cell carcinoma affecting the head and neck region. Another promising candidate, VB6-845d, is being developed to address a range of anti-epithelial cell adhesion molecule-positive solid tumors. Sesen Bio is also collaborating with Leiden University Medical Center on the joint development of an imaging agent. Originally incorporated in 2008, the company operated as Eleven Biotherapeutics, Inc. before rebranding as Sesen Bio, Inc. in May 2018. Its corporate headquarters are situated in Cambridge, Massachusetts.
Hisse Fiyatı
$0.6288
Son senkronizasyon: 2023-03-07
Piyasa Değeri
$6.00M
Değişim (1 gün)
7.29%
Değişim (1 yıl)
0.00%
Ülke
US
Ticaret Sesen Bio, Inc. (SESN)

Kategori

Sesen Bio, Inc. (SESN) için EPS
2026 itibariyle EPS TTM: 0
Sesen Bio, Inc. şirketinin en son finansal raporlarına ve hisse senedi fiyatına göre, şirketin mevcut EPS'si (TTM) 0'dir. 2026 yılı sonunda, şirketin EPS'si 0 idi; bu, 2026 yılındaki EPS olan 0 ile önceki yıla eşit.
Sesen Bio, Inc. için 2026 - 2026 arasındaki EPS geçmişi
Her yıl sonunda EPS
Yıl EPS Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakipler için EPS